Loading
companiesCompany
Geneoscopy
A St. Louis diagnostics company whose ColoSense stool RNA test became, in 2024, the first RNA-based colorectal cancer screening test approved in the United States.
Also called: ColoSense
Overview
Geneoscopy was founded by Washington University alumni to develop diagnostics from RNA shed by cells of the gut lining into stool. Its first product, ColoSense, combines eight RNA markers with a faecal immunochemical test for blood and was approved by the FDA in May 2024 for colorectal cancer screening in average-risk adults aged 45 and over, on the strength of the CRC-PREVENT study. The company positions stool RNA as less prone to the age-related false positives of stool DNA methylation tests and is developing further gut RNA tests, including for inflammatory bowel disease.
Headquarters
St. Louis, Missouri, United States, US
Type
Stage
Growth stage
Website
Similar pages
- CompanyNorgine
Shares Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), Colorectal cancer.
- CompanyZeria Pharmaceutical
Shares Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), Colorectal cancer.
- TrialUK Flexible Sigmoidoscopy Screening Trial
Shares Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), Colorectal cancer.
- PersonHermann Brenner
Shares Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), Colorectal cancer.
- IdeaPersonalised stool-test cut-offs by age, sex and prior results
Shares Multitarget stool RNA test (ColoSense), Colorectal cancer.
- TrialECLIPSE (Shield blood test)
Shares Multitarget stool RNA test (ColoSense), Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), Colorectal cancer.
- CollectionColorectal Cancer Alliance
Shares Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), Colorectal cancer.
- TrialNational Polyp Study
Shares Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), Colorectal cancer.